Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

NCT04389073 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

138

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Vinorelbine 40mg
BIOLOGICAL: Toripalimab 240mg
BIOLOGICAL: Bevacizumab 5 mg/kg
DRUG: Cyclophosphamide 50 mg
DRUG: Capecitabine 500Mg Oral Tablet
DRUG: Cisplatin

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborators

[object Object]